Claims
- 1. A compound of the formula: ##STR192## and the pharmaceutically acceptable acid addition salts thereof: wherein R.sup.1 is hydrogen, lower alkyl, hydroxy, lower alkoxy, --OCO.sub.2 -- lower alkyl, O(CH.sub.2).sub.m -phenyl with the phenyl optionally substituted by a member of the group comprising halogen, --NO.sub.2, --CN, --NH.sub.2, or lower alkyl;
- wherein m is an integer from 1 to 4;
- wherein R.sup.2 and R.sup.3 represent lower alkyl, halogen or lower alkoxy, or either one of R.sup.2 or R.sup.3 is hydrogen and the other is lower alkyl, halogen or lower alkoxy;
- wherein R.sup.5, R.sup.7, R.sup.8 and R.sup.9 may be the same or different and represent hydrogen or lower alkyl; wherein R.sup.10 is selected from the group consisting of --(ALK)X,
- wherein ALK represents alkylene, tnioalkylene, or oxyalkylene having 1 to 5 carbon atoms; alkenylene or alkynylene having 2 to carbon atoms; and
- wherein when ALK is alkylene, then X represents diphenylmethyl or substituted phenyl, and wherein the substituent on the substituted phenyl is methylene dioxy, carboxy, lower alkoxycarbonyl, carboxamide, cyano or dilower alkylamino and when ALK is not alkylene, then X represents diphenylmethyl, unsubstituted phenyl or substituted phenyl and wherein the substituent on the substituted phenyl is amino, hydroxy, halogen, nitro, methylenedioxy, lower alkyl, carboxy, lower alkoxycarbonyl, lower alkoxy, carboxamide, cyano or dilower alkylamino;
- wherein V represents an asymmetric carbon atom that may be racemic or have the D or L configuration; and wherein W represents an asymmetric carbon atom when R.sup.7 and R.sup.8 are not the same which may be racemic or have the D or L configuration.
- 2. A compound according to claim 1 of the formula: ##STR193## wherein R.sup.10 is selected from the group consisting of --(ALK)X, wherein ALK represents alkylene, thioalkylene, or oxyalkylene having 1 to 5 carbon atoms; alkenylene or alkynylene having 2 to 4 carbon atoms; and
- wherein when ALK is alkylene, then X represents diphenylmethyl or substituted phenyl and wherein the substituent on the substituted phenyl is methylenedioxycarboxy, lower alkoxycarbonyl, carboxamide, cyano or dilower alkylamino and when ALK is not alkylene, then X represents diphenylmethyl, unsubstituted phenyl or substituted phenyl wherein the substituent on the substituted phenyl is amino, hydroxy, halogen, nitro, methylenedioxy, lower alkyl, carboxy, lower alkoxycarbonyl, lower alkoxy, carboxamide, cyano or dilower alkylamino; and
- wherein V and W represent asymmetric carbon atoms that may independently be racemic or have the D and L configuration.
- 3. A compound according to claim 2 wherein ALK is --CH.sub.2 --CH.sub.2 --CH.sub.2 -- and wherein X is a member of the group consisting of p-dimethylaminophenyl, p-carboxyphenyl, p-lower alkoxycarbonylphenyl, 3,4-methylenedioxyphenyl, p-cyanophenyl and p-aminocarbonylphenyl.
- 4. A compound according to claim 2 wherein (ALK)X is ##STR194##
- 5. A compound according to claim 3, which is 2,6-dimethyltyrosyl-N-[3-(4-methoxyphenyl)propoxy]-D-alaninamide, hydrochloride, and the diastereomers thereof.
- 6. A compound according to claim 2, which is 2,6-dimethyltyrosyl-N-(3-phenyl-2E-propenyl)-D-alaninamide, hydrochloride, and the diastereomers thereof.
- 7. A compound according to claim 2, which is 2,6-dimethyltyrosyl-N-[3-(4-cyanophenyl)-2E-propenyl]-D-alaninamide, hydrochloride, and the diastereomers thereof.
- 8. A compound according to claim 3, which is 2,6-dimethyltyrosyl-N-[(4-cyanophenyl)propyl]-D-alaninamide, hydrochloride, and the diastereomers thereof.
- 9. A compound according to claim 3, which is 2,6-dimethyltyrosyl-N-[3-(1,3-benzodioxol-5-yl)propyl]-D-alaninamide, hydrochloride, and the diastereomers thereof.
- 10. A compound according to claim 1, which is 2,6-dimethyltyrosyl-N-(1S-methyl-3-phenylpropyl)-D-alaninamide, hydrochloride, and the diastereomers thereof.
- 11. A compound according to claim 4, which is 2,6-dimethyltyrosyl-N-[2-(phenylthio)ethyl]-D-alaninamide, hydrochloride, and the diastereomers thereof.
- 12. A compound according to claim 4, which is 2,6-dimethyltyrosyl-N-(2-phenyloxyethyl)-D-alaninamide, hydrochloride, and the diastereomers thereof.
- 13. A compound according to claim 3, which is 2,6-dimethyl-DL-tyrosyl-N-[3-[4-(dimethylamino)-phenyl]-propyl]-D-alaninamide, hydrochloride, and the diastereomers thereof.
- 14. A compound according to claim 2, which is 2,6-dimethyl-DL-tyrosyl-N-(1-methyl-3-phenylpropyl)-D-alaninamide.
- 15. A compound according to claim 2, which is 2,6-dimethyl-DL-tyrosyl-N-[3-[4-(methoxycarbonyl)phenyl]-propyl]-D-alaninamide, hydrochloride.
- 16. A compound according to claim 2, which is 2,6-dimethyl-D-tyrosyl-N-(3-phenyl-2-propynyl)-D-alaninamide, hydrochloride.
- 17. A compound according to claim 2, which is 2,6-dimethyl-L-tyrosyl-N-(3-phenyl-2-propynyl)-D-alaninamide, hydrochloride.
- 18. A compound according to claim 2, which is 2,6-dimethyl-D-tyrosyl-N-(3-phenyl-2Z-propenyl)-D-alaninamide, hydrochloride.
- 19. A compound according to claim 2, which is 2,6-dimethyl-L-tyrosyl-N-(3-phenyl-2Z-propenyl)-D-alaninamide, hydrochloride.
- 20. A compound according to claim 3, which is 2,6-dimethyl-tyrosyl-N-[3-(4-aminocarbonylphenyl)propyl]-D-alaninamide, hydrochloride, and the diastereomers thereof.
- 21. A compound according to claim 20, which is 2,6-dimethyl-D-tyrosyl-N-[3-(4-aminocarbonylphenyl)propyl]-D-alaninamide, hydrochloride.
- 22. A compound according to claim 2, which is 2,6-dimethyltyrosyl-N-(3,3-diphenylpropyl)-D-alaninamide, hydrochloride, and the diastereomers thereof.
- 23. A pharmaceutical composition for treating pain in mammals comprising a therapeutically effective amount of a compound according to claim 1 in a pharmaceutically acceptable carrier.
- 24. A method for treating pain in mammals comprising administering a therapeutically effective amount of a compound according to claim 1 to a mammal in need of such treatment.
Parent Case Info
This is a continuation-in-part of Ser. No. 829,266 filed Feb. 14, 1986, now abandoned which is a continuation-in-part of Ser. No. 765,882 filed Aug. 14, 1985, now abandoned.
US Referenced Citations (10)
Non-Patent Literature Citations (2)
Entry |
Kiso et al., Synthesis and Activity of Short Chain Enkephalin-Like Peptides Peptide Chemistry 1981, T. Shiori (Ed), Protein Res. Foundation, Osaka (1982). |
Vavarek et al., Peptides, vol. 2 pp. 303-308 (1981). |
Continuation in Parts (2)
|
Number |
Date |
Country |
Parent |
829266 |
Feb 1986 |
|
Parent |
765882 |
Aug 1985 |
|